Literature DB >> 25495088

Risk-benefit analysis of antidepressant drug treatment in the elderly.

Cecilio Alamo1, Francisco López-Muñoz, Pilar García-García, Silvia García-Ramos.   

Abstract

Depression in the elderly is a significant health issue that has the potential to seriously affect physical and emotional well-being. Therefore, the treatment of geriatric depression is necessary. Antidepressant treatment in older depressed patients is efficacious, but differences in the effectiveness of different classes of antidepressants have not been demonstrated. However, differences in tolerability profile are most recognizable in the elderly. With ageing, a series of changes occur in the elderly that modify both the pharmacokinetics and pharmacodynamics of antidepressants and may influence the efficacy, tolerability and safety of treatment in the elderly. Comorbidities require the use of other drugs, which increases the possibility of drug-drug interactions. Given these aspects, individualized therapy for each elderly patient is needed to achieve acceptable risk-benefit ratio. Effective treatment of depression in the elderly, which may require combined pharmacological with psychosocial treatment, can decrease both morbidity and mortality; it also may lead to reduced demands on family members and on health-care and social services.
© 2014 The Authors. Psychogeriatrics © 2014 Japanese Psychogeriatric Society.

Entities:  

Keywords:  antidepressant drugs; depression; elderly; risk-benefit analysis

Mesh:

Substances:

Year:  2014        PMID: 25495088     DOI: 10.1111/psyg.12057

Source DB:  PubMed          Journal:  Psychogeriatrics        ISSN: 1346-3500            Impact factor:   2.440


  9 in total

Review 1.  Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.

Authors:  Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

Review 2.  Advances and Barriers for Clinical Neuroimaging in Late-Life Mood and Anxiety Disorders.

Authors:  Maria Ly; Carmen Andreescu
Journal:  Curr Psychiatry Rep       Date:  2018-03-01       Impact factor: 5.285

3.  Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case-Control Study.

Authors:  Wiebke Schäfer; Christina Princk; Bianca Kollhorst; Tania Schink
Journal:  Drug Saf       Date:  2019-09       Impact factor: 5.606

4.  The Impact of Age on Propofol Requirement for Inducing Loss of Consciousness in Elderly Surgical Patients.

Authors:  Hua Yang; Hui-Min Deng; Hai-Yan Chen; Shu-Heng Tang; Fang Deng; Yu-Gang Lu; Jin-Chao Song
Journal:  Front Pharmacol       Date:  2022-03-28       Impact factor: 5.810

5.  Trajectories of depressive symptoms after hip fracture.

Authors:  P Cristancho; E J Lenze; M S Avidan; K S Rawson
Journal:  Psychol Med       Date:  2016-05       Impact factor: 7.723

Review 6.  Mood disorders in the elderly: prevalence, functional impact, and management challenges.

Authors:  Leandro da Costa Lane Valiengo; Florindo Stella; Orestes Vicente Forlenza
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-24       Impact factor: 2.570

7.  Distinct Antidepressant-Like and Cognitive Effects of Antidepressants with Different Mechanisms of Action in Middle-Aged Female Mice.

Authors:  Yan Li; Connie Sanchez; Maria Gulinello
Journal:  Int J Neuropsychopharmacol       Date:  2017-06-01       Impact factor: 5.176

Review 8.  Optimal management of ADHD in older adults.

Authors:  Terje Torgersen; Bjorn Gjervan; Michael B Lensing; Kirsten Rasmussen
Journal:  Neuropsychiatr Dis Treat       Date:  2016-01-08       Impact factor: 2.570

Review 9.  The Role of Physical Exercise and Omega-3 Fatty Acids in Depressive Illness in the Elderly.

Authors:  Stefano Farioli Vecchioli; Stefano Sacchetti; V Nicolis di Robilant; Debora Cutuli
Journal:  Curr Neuropharmacol       Date:  2018-03-05       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.